

Supplementary Table S1. Main characteristics of the included studies in this systematic review.

| Reference | Authors | Year | Type of study | Study object (sample size (if applicable)) | Studied compound/extract | Methodology | Evaluated parameters |
|-----------|-------------------------|------|-----------------|---|---|--|---|
| 1 | Gonçalves <i>et al.</i> | 2022 | <i>In vitro</i> | NHDF cells | <i>P. viridis</i> , <i>B. caapi</i> , <i>M. hostilis</i> , <i>P. harmala</i> and a commercial mixture beverages | MTT assay; Wound-Healing assay; Parallel Artificial Membrane Permeability assay | Wound-Healing Potential |
| 7 | Gonçalves <i>et al.</i> | 2020 | <i>In vitro</i> | <i>Staphylococcus aureus</i> , <i>Bacillus cereus</i> , <i>Listeria monocytogenes</i> , <i>Enterococcus faecalis</i> , <i>Acinetobacter baumannii</i> , <i>Pseudomonas aeruginosa</i> , <i>Escherichia coli</i> , and <i>Salmonella Typhimurium</i> | <i>P. viridis</i> , <i>B. caapi</i> , <i>M. hostilis</i> , <i>P. harmala</i> and a commercial mixture beverages | Folin–Ciocalteu colorimetric method; aluminum chloride colorimetric method; DPPH Scavenging Assay; -Carotene Bleaching Test; protein denaturation inhibition assay; Disc Diffusion Assay; Resazurin Microtiter Method; Anti-Quorum Sensing Properties: Solid Diffusion Assay; Anti-Biofilm Activity evaluation by scanning electron microscopy | Antioxidant, Anti-Inflammatory and Antimicrobial activity |
| 14 | Andrade <i>et al.</i> | 2018 | <i>In vivo</i> | Zebrafish (not specified) | Ayahuasca beverage | Fish embryo toxicity test; behavioral assessment | Embryo development effects and neurobehavior |
| 18 | Riba <i>et al.</i> | 2003 | Clinical trial | Human volunteers (18) | Ayahuasca beverage | Visual analog scales; Hallucinogen Rating Scale; Addiction Research Center Inventory; | Subjective and cardiovascular effects and alkaloid pharmacokinetics |

| | | | | | | | |
|----|----------------------------|------|------------------------|---------------------------|-----------------------|---|---|
| | | | | | | Cardiovascular Measures; Pharmacokinetic Analysis | |
| 20 | Riba <i>et al.</i> | 2006 | Clinical trial | Human volunteers (15) | Ayahuasca beverage | Hallucinogen Rating Scale; Addiction Research Center Inventory; single photon emission tomography imaging | Regional cerebral blood Flow effects |
| 26 | Kuypers <i>et al.</i> | 2016 | Ayahuasca ritual | Human volunteers (26) | Ayahuasca beverage | Pattern/line meanings test; picture concept test; visual analog scales | Creative thinking effects |
| 27 | Silva <i>et al.</i> | 2022 | <i>In vivo</i> | Rats (80) | Ayahuasca beverage | Open field test; forced swimming test | Behavioral response in neuroinflammation |
| 28 | Correa-Netto <i>et al.</i> | 2017 | <i>In vivo</i> | Mice (8- 12/group) | Ayahuasca beverage | Behavioral tests; Open field test; elevated plus maze tasks; Morris water maze | Memory and anxiety effects |
| 29 | Sanches <i>et al.</i> | 2016 | Clinical trial | Human volunteers (17) | Ayahuasca beverage | Hamilton Rating Scale for Depression, the Montgomery-Åsberg Depression Rating Scale; Brief Psychiatric Rating Scale; Young Mania Rating Scale; Clinician Administered Dissociative States Scale | Anti-depressive potentials and its effects on regional cerebral blood flow |
| 30 | Santos <i>et al.</i> | 2007 | Observational study | Human volunteers (9) | Ayahuasca beverage | Standard questionnaires to evaluate state-anxiety, trait- anxiety, panic-like and hopelessness | Psychometric measures of anxiety, panic-like and hopelessness effects |
| 31 | Mian <i>et al.</i> | 2019 | Observational study | Human volunteers (152) | Ayahuasca beverage | Behavioral Activation for Depression Scale-Short | Contribution of mindfulness and |

| | | | | | | | |
|----|------------------------------|------|---------------------|----------------------------------|--------------------|--|---|
| | | | | | | Form; Five Facet Mindfulness Questionnaire; Experiences Questionnaire; Center for Epidemiological Sciences Depression Short Form | behavioral activation in anti-depressant effects |
| 32 | Nolli <i>et al.</i> | 2020 | <i>In vivo</i> | Wistar rats (64) | Ayahuasca beverage | cFos immunohistochemistry | Treatment to decrease ethanol intake; neural activity effects |
| 33 | Talin <i>et al.</i> | 2017 | Observational study | Human volunteers (not specified) | Ayahuasca beverage | Long-term fieldwork and participant observation in ayahuasca communities | Interactive ritual contexts support on the healing effort |
| 34 | Loizaga-Velder <i>et al.</i> | 2014 | Observational study | Human volunteers (not specified) | Ayahuasca beverage | Review of therapeutic projects; interviews with therapists who apply ayahuasca in the treatment of addictions; interviews with expert researchers on the topic; interviews with individuals who had undergone ayahuasca-assisted therapy for addiction in diverse treatment settings | Substance dependence treatment |
| 35 | Peláez <i>et al.</i> | 2020 | Observational study | Human volunteers (14) | Ayahuasca beverage | Scale Temperament and Character Inventory–Revisited; Cloninger’s model | Personality traits |
| 36 | González <i>et al.</i> | 2019 | Observational | Human | Ayahuasca | General Characteristics | Grief therapy |

| | | | | | | | |
|----|-----------------------|------|------------------------|---------------------------|-----------------------|---|---|
| | | | study | volunteers (60) | beverage | Bereavement Questionnaire; Texas Revised Inventory of Grief; Acceptance and Action Questionnaire; Ethical Considerations | |
| 37 | Uthaug <i>et al.</i> | 2018 | Ayahuasca ritual | Human volunteers (57) | Ayahuasca beverage | Picture concept task; Depression, Anxiety, and Stress Scale-21; Satisfaction with Life Scale; Five Facets Mindfulness Questionnaire; Ego Dissolution Inventory | Well-being and cognitive thinking style effects; Depend on the degree of ego dissolution effects |
| 38 | Uthaug <i>et al.</i> | 2021 | Clinical trial | Human volunteers (30) | Ayahuasca beverage | Multifaceted empathy test; Ego Dissolution Inventory; the 5-Dimensional Altered States of Consciousness Rating Scale; Depression, Anxiety, and Stress Scale 21; Brief Symptom Inventory 18; Five Facets Mindfulness Questionnaire | Mental health changes |
| 39 | Soler <i>et al.</i> | 2016 | Observational study | Human volunteers (25) | Ayahuasca beverage | Five Facets Mindfulness Questionnaire; Experiences Questionnaire | Psychological mechanisms underlying the beneficial effects |
| 40 | Harris <i>et al.</i> | 2012 | Observational study | Human volunteers (177) | Ayahuasca beverage | Qualitative questionnaire | Effects on joy in life, relationship to the sacred and toxic feelings |
| 41 | Barbosa <i>et al.</i> | 2005 | Observational study | Human volunteers (28) | Ayahuasca beverage | Clinical Interview Schedule- Revised Edition; | Psychological aspects in mental |

| | | | | | | | |
|----|-------------------------------|------|---------------------|------------------------|--------------------|--|--|
| | | | | | | Sociodemographic profile; Inventory of intrinsic religious beliefs profiles; Inventory of expectancies/motivations; Phenomenological mapping of the altered states of Consciousness; Behavioral changes inventory | health |
| 42 | Riba <i>et al.</i> | 2001 | Clinical trial | Human volunteers (6) | Ayahuasca beverage | Visual analogue scales; Spanish adaptations of the Hallucinogen Rating Scale; Addiction Research Center Inventory; Tolerability measures | Psychological effects and tolerability |
| 43 | Domínguez-Clavé <i>et al.</i> | 2019 | Observational study | Human volunteers (45) | Ayahuasca beverage | Difficulties in Emotion Regulation Scale; mindfulness traits (Five Facet Mindfulness Questionnaire–Short Form; Experiences Questionnaire | Emotion regulation and mindfulness-related abilities effects |
| 44 | Franquesa <i>et al.</i> | 2018 | Observational study | Human volunteers (122) | Ayahuasca beverage | Brief Symptom Inventory 18 scale; Psychoticism scale of the Symptoms Assessment-45; Experiences Questionnaire; Engaged Living Scale; Experiencing of Self Scale | Link between Decentering, Values and Self |
| 45 | Frecka <i>et al.</i> | 2012 | Ayahuasca ritual | Human volunteers (61) | Ayahuasca beverage | Torrance Tests of Creative Thinking | Creativity and expression of |

| | | | | | | | |
|----|-----------------------------|------|------------------------------------|--|----------------------------|---|---|
| | | | | | | | creativity |
| 46 | Weiss <i>et al.</i> | 2021 | Ayahuasca ritual | Human volunteers (256) | Ayahuasca beverage | Changes in personality traits by the Five-Factor model; demographic characteristics, baseline personality, and acute post-ayahuasca experiences | Personality changes |
| 47 | Campagnoli <i>et al.</i> | 2020 | Ayahuasca ritual | Human volunteers (9) | Ayahuasca beverage | Hearing and reproduction of musical stimuli | Effects of listening to musical stimuli on subjective time |
| 48 | Trichter <i>et al.</i> | 2009 | Observational study | Human volunteers (54) | Ayahuasca beverage | Peak Experience Profile; Spiritual Well-being Scale; Mysticism Scale | Influence on spirituality |
| 49 | Bussmann <i>et al.</i> | 2010 | <i>In vitro</i> | <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> | 141 plant species | Minimal inhibitory concentration | Minimum inhibitory concentration and antibacterial properties determination |
| 50 | Liu <i>et al.</i> | 2017 | <i>In vitro</i> and <i>in vivo</i> | HEK-293T cells and mice (not specified) | <i>P. harmala</i> beverage | Gene reporter assay; Determination of nitric oxide production; Enzyme-linked immunosorbent assay; Quantitative real-time PCR; Immunofluorescence staining and microscopic imaging; H&E staining | Anti-inflamató Anti-inflammatory effects |
| 51 | Galvão-Coelho <i>et al.</i> | 2020 | Clinical trial | Human volunteers (73) | Ayahuasca beverage | Blood inflammatory biomarkers measure; Montgomery-Åsberg | Blood inflammatory biomarkers |

| | | | | | | | |
|----|--------------------------------|------|------------------------------------|---|--|--|---|
| | | | | | | Depression Rating Scale | |
| 52 | Katchborian-Neto <i>et al.</i> | 2020 | <i>In vitro</i> | SH-SY5Y neuroblastoma cells | <i>P. viridis</i> , <i>B. caapi</i> extracts and Harmine and DMT | MTT assay; Ki-67 staining (cell proliferation); calcein-AM/PI staining | Neuroprotector potential |
| 53 | Morales-Garcia <i>et al.</i> | 2020 | <i>In vitro</i> and <i>in vivo</i> | neural stem cells and C57/BL6 mice (24) | DMT | Growth and proliferation measurements; differentiation of cultures; western blot analysis; immunocytochemistry; immunohistochemistry; cell count analysis; behavioral studies | Neurogenic effects |
| 54 | Samoylenko <i>et al.</i> | 2010 | <i>In vitro</i> | Recombinant human brain monoamine oxidase -A and -B | <i>B. caapi</i> extracts | Inhibition kinetics assay; cytotoxicity assay; Determination of ROS assay; Ensaio de inibição da atividade das enzimas acetilcolinesterase, butirilcolinesterase e catecol-O-metil transferase | Prevention of neurological disorders through the antioxidant and inhibitory activity of Monoamine Oxidase |
| 55 | Schwarz <i>et al.</i> | 2003 | <i>In vitro</i> | Wistar rats liver | <i>B. caapi</i> extract, harmine and harmaline | MAO inhibition assay; <i>In vitro</i> release of [3H]dopamine ([3H]DA) | Investigation of <i>in vitro</i> activity relevant to Parkinson's Disease |
| 56 | Bouso <i>et al.</i> | 2013 | Observational study | Human volunteers (24) | Ayahuasca beverage | Tower of London task; Stroop color and word test; Sternberg working memory task | Neuropsychological performance (working memory and executive function) effects |
| 57 | Lafrance <i>et al.</i> | 2017 | Observational | Human | Ayahuasca | Interview with questions of | Potential |

| | | | study | volunteers (16) | beverage | etiological, clinical, and treatment histories | therapeutic in eating disorders |
|----|-----------------------------|------|---------------------|-----------------------|--------------------|---|------------------------------------|
| 58 | Santos <i>et al.</i> | 2012 | Clinical trial | Human volunteers (17) | Ayahuasca beverage | visual analog scales; Hallucinogen Rating Scale; Addiction Research Center Inventory; Neurophysiological measures; Cardiovascular measures; Autonomic measures; Neuroendocrine measures | Tolerance or sensitization effects |
| 59 | Halpern <i>et al.</i> | 2008 | Observational study | Human volunteers (32) | Ayahuasca beverage | Structured Clinical Interview for DSM-IV Disorders; 14-item Hamilton Anxiety Rating Scale; 21-item Hamilton Depression Rating Scale; Symptom Check List 90 Revised; Uplifts, Hassles, Stresses, and Cognitive Failures questionnaire; Wender Utah Rating Scale for attention-deficit hyperactivity Disorder; Structured Clinical Interview for DSM-IV Axis II Personality Disorders | Beneficial effects |
| 60 | Mello <i>et al.</i> | 2018 | Clinical trial | Human volunteers (22) | Ayahuasca beverage | Evaluation of biochemical parameters | Hepatic biochemical parameters |
| 61 | Madrid-Gambin <i>et al.</i> | 2022 | Clinical trial | Human volunteers (23) | Ayahuasca beverage | 5-Dimension Altered States of Consciousness Rating | Human metabolomics |

| | | | | | | Scale | signature investigation |
|----|-------------------------|------|-----------------|----------------------------|--------------------|---|---|
| 62 | Riba <i>et al.</i> | 2002 | Clinical trial | Human volunteers (18) | Ayahuasca beverage | Topographic quantitative-electroencephalography; Hallucinogen Rating Scale | Cerebral bioavailability and time-course |
| 63 | Schenberg <i>et al.</i> | 2015 | Clinical trial | Human volunteers (30) | Ayahuasca beverage | Hallucinogen Rating Scale-Brazilian Version; Electroencephalography | Effects of oscillatory activity of different brain regions |
| 64 | Brierley <i>et al.</i> | 2013 | <i>In vitro</i> | Rat brain slices | Harmine | Fast cyclic voltammetry; Carbon fibre microelectrodes | Acute effects and pharmacological mechanism on electrically evoked dopamine efflux parameters |
| 65 | Santos <i>et al.</i> | 2011 | Clinical trial | Human volunteers (10) | Ayahuasca beverage | Hallucinogen Rating Scale; Addiction Research Center Inventory; autonomic measures; neuroendocrine measures; lymphocyte subpopulations measures; electroencephalographic measures | Autonomic, neuroendocrine, and immunomodulatory effects |
| 66 | Dakic <i>et al.</i> | 2016 | <i>In vitro</i> | Human embryonic stem cells | Harmine | Cell proliferation (Immunocytochemistry); cell death; DNA damage | proliferation of human neural progenitor effects |
| 67 | Riba <i>et al.</i> | 2004 | Clinical trial | Human volunteers (18) | Ayahuasca beverage | Hallucinogen Rating Scale; self-report questionnaire measuring psychedelic-induced subjective effects; | Changes in brain electrical activity |

| | | | | | | | |
|----|-----------------------------|------|----------------|-----------------------|--------------------|--|--|
| | | | | | | topographic pharmacoelectroencephalography; low-resolution electromagnetic tomography | |
| 68 | Viol <i>et al.</i> | 2017 | Clinical trial | Human volunteers (10) | Ayahuasca beverage | Complex networks measures | Differences in complex networks with and without ayahuasca influence |
| 69 | Alvarenga <i>et al.</i> | 2014 | <i>In vivo</i> | Rats (80) | Ayahuasca beverage | Sexual behavior evaluation; paradoxical sleep deprivation; hormone concentrations evaluation | Sexual performance (sleep deprived) |
| 70 | Barbanoj <i>et al.</i> | 2008 | Clinical trial | Human volunteers (22) | Ayahuasca beverage | Subjective sleep quality; polysomnography; spectral analysis | Sleep parameters effects |
| 71 | Riba <i>et al.</i> | 2002 | Clinical trial | Human volunteers (18) | Ayahuasca beverage | P50 elicitation and recording; Startle reflex elicitation and recording; Hallucinogen Rating Scale; Spanish version of the Altered States of Consciousness Questionnaire | P50 suppression and PPI effects |
| 72 | Oliveira-Lima <i>et al.</i> | 2015 | <i>In vivo</i> | Mice (146) | Ayahuasca beverage | Open-field test | Ethanol treatment |
| 73 | Pitol <i>et al.</i> | 2015 | <i>In vivo</i> | Rats (40) | Ayahuasca beverage | Morphometric Analysis (qualitative and quantitative) | Structural parameters in aorta effects |
| 74 | Serra <i>et al.</i> | 2022 | <i>In vivo</i> | Mice (90) | Ayahuasca beverage | behavioral observation | Role of 5-HT _{2A} receptors in the |

| | | | | | | | |
|----|--------------------------|------|------------------|--|--|--|--|
| | | | | | | | treatment of ethanol withdrawal |
| 75 | Frecska <i>et al.</i> | 2004 | Clinical trial | Human volunteers (10) | Ayahuasca beverage | Binocular rivalry test | Influence of binocular rivalry on high rates of dichotic stimulus alternation investigation |
| 76 | Frecska <i>et al.</i> | 2003 | Ayahuasca ritual | Human volunteers (10) | Ayahuasca beverage | Binocular rivalry test | Influence of binocular rivalry in revealing the temporal characteristics of brain dominance in an altered state of consciousness investigation |
| 77 | Kummrow <i>et al.</i> | 2019 | <i>In vitro</i> | TA98 and TA100 strains of <i>Salmonella enterica</i> serovar Typhimurium | <i>P. viridis</i> and <i>B. caapi</i> beverages; Harmine and harmaline | Salmonella/Microsome Assay | Mutagenicity |
| 78 | Colaço <i>et al.</i> | 2020 | <i>In vivo</i> | Wistar rats (85) | Ayahuasca beverage | Open field test; elevated-plus-maze apparatus test; hematological and biochemical evaluation | Toxic effects |
| 79 | Pic-Taylor <i>et al.</i> | 2015 | <i>In vivo</i> | Wistar rats (6/condition) | Ayahuasca beverage (<i>P. viridis</i> and <i>B. caapi</i>) | Open field, elevated plus maze, and forced swimming tests; neuronal activation (c-fos marked neurons); toxicity (Fluoro- | Behavioural and neurotoxic effects |

| | | | | | | | |
|----|---------------------|------|-----------------|--------------------|---|---|-------------------------------------|
| | | | | | | Jade B and Nissl/Cresyl staining) | |
| 80 | Motta <i>et al.</i> | 2018 | <i>In vivo</i> | Rats (130) | Ayahuasca beverage | Histological evaluation | Maternal and developmental toxicity |
| 81 | Simão <i>et al.</i> | 2020 | <i>In vitro</i> | Dopaminergic cells | <i>P. viridis</i> , <i>B. caapi</i> , <i>M. hostilis</i> , <i>P. harmala</i> and a commercial mixture beverages | Cellular viability assay; protein quantification; | Cytotoxicity |